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Review Article
MORTALITY PATTERN AMONG TUBERCULOSIS PATIENTS ON TREATMENT IN 
NIGERIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
ABSTRACT
Background: Tuberculosis (TB) has continued to be associated with a substantial number of deaths, even in the era of 
effective antimicrobials. Nigeria is one of the countries with a high tuberculosis burden and has sub-optimal documentation 
of TB related deaths. Vital statistics/registration is not robust, and mortality surveys are rarely undertaken. In this study, we 
aimed to determine a precise estimate of TB related deaths on treatment and the trends in death rate while on TB treatment 
in Nigeria.
st stMethods: We searched electronic databases for eligible studies from 1  January 2000 to 31  December 2017. We generated 
pooled death rate estimates using random-effects models and determined trends using meta-regression.
Results: We identified 546 studies, of which 28 fulfilled the criteria for quantitative analysis. Overall, studies reported on 
64,999 individuals. The pooled TB death rate during treatment was 6.6% (95% CI; 5.2-8.1%). There was a non-significant rise 
in TB related deaths on treatment of 0.2% per year (p-value = 0.454).
Conclusion: We found a low TB related deaths on treatment, death rate and slight temporal rise over the study years. There is 
a need for continuous vital registration, including TB related death, and mortality survey among TB patients.
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n 2016 the World Health Organization (WHO) 
estimated Tuberculosis (TB) mortality of 17(16-
19)/100,000 population among its 194 member states, I
with 22 high burden countries making a significant 
1contribution.  Nigeria is among these high burden 
countries with a TB incidence and mortality of 
1307,000/100,000 and 115,000/100,000, respectively.  
Mortality data for TB had been obtained from vital 
2registrations (VR) and mortality surveys ; however, VR is 
not robust, and mortality surveys are infrequently done in 
3many developing countries, including Nigeria.  
Tuberculosis related mortality has been a measure of the 
efficiency of TB control and, as such, it is a prime focus for 
4, 5policymakers.  Although concerted efforts to reduce TB 
death has been ongoing, it is not without challenges. 
Curbing death from TB has been limited by low case 
detection, increasing occurrence of TB drug resistance, 
6 economic impediments and limited access to TB care.
Furthermore, in spite of attempts at achieving a fairly 
representative spread of national TB treatment centres 
across Nigeria, TB is still associated with death and 
disability in addition to the indirect cost incurred in an 
7effort to seek care.  
With concerns about the completeness of VR and TB case 
reporting in Nigeria, it is likely that TB prevalence and 
1,8mortality are underestimated.  To improve the reliability 
of accessible data on TB mortality, repeated community-
based surveys would be required not only to appreciate the 
burden but also to establish trends. In the interim, a meta-
analysis of observational studies in epidemiology 
(MOOSE) technique could be used to enhance the validity 
of available data. To address this gap, we conducted a 
meta-analysis to estimate TB mortality rate and trends in 
patients initiated on TB treatment in Nigeria. 
METHODS
Search strategy
We searched databases such as   (PubMed) EMBASE 
AJOL, BIOLINE, Google scholar and LILACS for studies 
reporting death among patients with TB.  We searched for 
literature spanning 1st January 2000 to 31st December 
2017. The search strategy combined keywords and medical 
subject headings (MeSH), using multiple search strategies: 
We used the search strategy of the free text terms 'death' 
AND 'tuberculosis' with the 'OR' operator including the 
evaluated MeSH headings 'tuberculosis' AND 'mortality' 
and 'Nigeria'. We searched retrieved articles in search of 
other relevant bibliographies. A manual search was done 
for pertinent literature in subject-specific speciality 
journals without online versions. Accessible authors were 
contacted concerning incomplete data.
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Eligibility criteria and study selection
Eligible studies comprised of clinical trials, retrospective 
and prospective cohort studies, cross-sectional studies, 
and case-control studies (with a report of mortality data) 
were assessed. We included studies reporting pulmonary 
and extrapulmonary TB with no sex or age restriction.
We did not include studies on high-risk populations (those 
with naturally exaggerated death rate) considering their 
potential to present exaggerated death frequency. 
Furthermore, presenting data before the year 2000, those 
with small sample size (which we defined as sample size 
less than 100) were excluded. We also excluded studies 
without primary data, commentaries, literature reviews, 
studies adjudged to have poor quality based on the NIH 
9criteria,  studies with inappropriate data,  and studies with 
inadequate data.
Data Extraction
Two independent reviewers assessed titles and abstracts. 
We obtained full-text articles of abstracts with information 
suggestive of fulfilling the inclusion criteria. We abstracted 
the following information from the eligible studies; name 
of first author's; year of publication; study design; study 
setting, age group of the study population, the study 
setting; anatomical site of TB infection (pulmonary / extra-
pulmonary) method of diagnosis, the order of TB 
treatment (new or retreatment), number of persons with 
TB, number of deaths while on TB treatment, TB/HIV 
death and TB death in HIV negative patients. Data was 
coded based on the author's name, and year of study.  We 
assessed Multiple Coder agreement based on Cohen's 
kappa.
Operational definitions:
Tuberculosis (TB) death was defined as individual dying 
during TB treatment (all-cause mortality). The primary 
outcome measure was the proportion of TB patients on TB 
treatment that died of TB within the designated period of 
study.
Quality of Included studies
Study quality was independently assessed by two authors 
using the NIH Quality Assessment Tool for Observational 
9Cohort and Cross-Sectional Studies.  We evaluated studies 
with queries appropriate to their study design. Study 
qualities were graded as good (G), fair (F) or poor (P) 
according to the rating of at least 70%, 50%, or lower than 
50%, respectively.
Statistical analyses
The primary outcome measure was the proportion of death 
from TB. We estimated standard error of proportions using 
a binomial probability distribution. Cumulative and sub-
group pooled effect size using a random-effect model with 
DerSimonian-Laird iteration was determined. A pooled 
proportion estimate and confidence interval, in accordance 
with the weighted least square (weighting is given by the 
reciprocal sum of,  between and within-study variances), 
was generated. Between study and heterogeneity using 
Cochran's Q test was evaluated. We a priori, defined low, 
medium and high heterogeneity as a Cochrane Q of 25%, 
50%, and 75%, respectively. We explored potential 
confounders and modelled proportion trends using meta-
regression. Publication bias with funnel plot, Begg's rank 
correlation methods and Egger's weighted regression test 
were assessed. Analyses using STATA software (version 
11) was performed. The significance level for Cochran's
test was fixed at 0.05. We did iteration sensitivity analysis 
to determine the effect of sample size variation on the 
aggregate proportion of TB death.
RESULTS
Characteristics of included studies
We found 546 citations of which 28 articles satisfied all 
inclusion criteria and were included in both qualitative 
10 - 37and quantitative summary (meta-analysis).  (Figure 1) 
These comprised of 25 retrospective cohort studies and 3 
prospective cohort studies with the characteristics of 
included studies as shown in Table 1. Compliance with 
meta-analysis guidelines was assessed using PRISMA and 
MOOSE checklist.
Quality assessment
Based on the 10 quality domains evaluated, all studies 
satisfied a minimum of six of the quality
criteria. A  number of  benchmark failed were: sample size 
justification, insufficient
sample size, study power description, or variance and 
effect estimates not properly documented.  All included 
studies had scores of at least 70%; details of the rating 
process is presented in Table 2.
Overall prevalence
Accordingly, our meta-analysis obtained an overall pooled 
TB related deaths on treatment prevalence in Nigeria of 
6.6% (95% CI; 5.2-8.1%). This was derived from the analysis 
of cumulative individual data from 64,999 individuals 
with TB, spanning 17 years (2000-2017). (Figure 2) 
Table 1 depicts subgroup analyses for the proportion of TB 
death based on several characterizations; namely study 
setting, study design, site of tuberculosis, year of study, age 
category, site of study, and disease category. Remarkable 
differences were noted in the proportion of TB related 
deaths on treatment.
The proportion of death among TB patients was higher in 
studies within a hospital setting with a prevalence of 4.9 % 
(95% CI: (4.6-5.2) compared to the proportion in the single 
large community-based study with a prevalence of 0.8% 
(95% CI: 0.7-0.9).
TB related deaths on treatment was higher in retrospective 
studies compared to prospective studies, with proportions 
of 5.8% (95% CI: 5.5-6.1) and 0.8% (95% CI: 0.7-0.9), 
respectively.
The proportion of death from pulmonary TB was 0.9% 
(95% CI: 0.8-0.9) compared to 5.9% (95% CI: 5.6-6.2) from 
both pulmonary and extra-pulmonary sites. When 
assessed based on year of study, proportions ranged from 
0.8% (95% CI: 0.7-0.9) in studies of 2015 to 8.6% (95% CI: 
7.5-9.7) in studies of 2003. The pooled proportion in adult 
populations yielded a higher proportion of TB related 
deaths on treatment with a figure of 4.3% (95% CI: 4.0-4.7). 
Conversely, studies restricted to the single site had a higher 
proportion with a value of 5.4% (95% CI: 5.0-5.7), 
compared to 1.0% (95% CI: 0.9-1.1) in studies involving 
multiple sites. Furthermore, studies reporting on new and 
re-treatment TB cases had a higher pooled proportion of TB 
related deaths on treatment, with a figure of 4.9% (95% CI: 
4.6-5.2)
The proportion TB related deaths on treatment among HIV 
negative TB patients was 5.2% (95% CI: 3.1-7.3) [ Figure 3]; 
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whereas the proportion was 3.6% (95% CI: 2.5-4.7) in those 
with TB/HIV co-infection. [Figure 4]
We sought evidence of a trend in the proportion of TB 
related deaths on treatment over the period 2000-2017 
using meta-regression modelling.
We found a non-significant rise in the proportion of TB 
related deaths on treatment among studied Nigerian 
populations at a rate of 0.2% per year (p-value = 0.454) 
[Figure 5]. There was no evidence of confounding using 
covariates: study setting, study design, site of tuberculosis, 
age category, site of study, and disease category.
We found no evidence of publication bias using Egger's 
and Begg's test statistics (p-value =0.101 for both tests). We 
used augmented data to model data symmetry on the 
funnel plot. We concluded no graphic evidence of 
publication bias since augmented plot depicted TB related 
deaths on treatment in the negative range, which is not 
biologically plausible. [Figure 6]
DISCUSSION
In this study, we have found a pooled TB death rate of 7% 
among persons on TB treatment in Nigeria. We have 
further shown evidence of a non-significant rise in the TB 
death rate over 17 years. Assuming that Nigeria had a TB 
1incidence of 219/100,000 population in 2016,  then we 
would be estimating an occurrence of TB related deaths on 
the treatment  of  15/100,000 population, with an 
uncertainty interval of (9-21 )/100,000 population. To our 
knowledge, this study, with an appraisal spanning 2000-
2017, is the most robust and extensive review of the burden 
of TB death in Nigeria so far. Moreover, it is the first study 
to assess the trend in the TB related deaths on treatment in 
Nigeria using meta-analysis modelling. 
Our finding is consistent with an earlier study by 
38Straetemans et al , which reported a  TB case fatality rate 
during treatment of 5.8% ( 95% CI:  3.1%–8.4%) using 
pooled data from 17 studies with global distribution. 
Several other Nigerian studies have found low death rate 
16, 24, 25among patients on TB treatment.  Nevertheless, 
findings from such studies do not consistently depict low 
15TB related deaths on treatment.    Our findings suggest a 
marginal lower TB death rate in HIV positive patients. 
Although TB could occur at any point along the spectrum 
of immunoparesis in HIV infection, perhaps our finding 
could be accounted for by the additive mortality benefit of 
 1, 39HIV treatment.
Although there is a decline in global TB related mortality, 
our data suggest a contrasting rising propensity among 
treated cases. WHO  had reported a similar trend as 
1depicted (graphically) in its 2017 Global TB report.
This finding underscores the need for sustained TB 
surveillance and VR documentation and reportage to serve 
as a veritable data source for TB control.  It equally serves 
as a mirror of the efficiency of national and global TB 
control interventions. In the context of global socio-
economic dynamics, assessing TB death trend is pertinent 
because of its critical role in gauging progress towards the 
“End TB Strategy”  milestones of percentage reduction in 
the absolute number of TB deaths (compared with 2015 
1baseline) of 35% by 2020, and 75% by 2025.
We found a striking difference in higher rates of TB related 
deaths on treatment in hospital-based studies compared to 
report from the community. This could be attributed to the 
likelihood of patients seen in the hospital being more sick 
40with late presentation.  Similarly, the disparity between 
retrospective and prospective studies could be due to 
variation in rigour between the two study designs. 
Retrospective design is more prone to bias on account of 
differences in coding and storing mortality data and recall 
41bias.  Tuberculosis programs by default rely on 
microscopic examination of sputum for diagnosis, with 
microscopy skill acquired over several years having a 
legacy effect, as such patients presenting with pulmonary 
TB are more likely to be diagnosed and commenced on 
42therapy early.  It is thus probable that they would have a 
lower death rate compared to those with extra-pulmonary 
manifestation. TB related deaths on treatment is higher in 
43children.  Although we found a lower death rate in 
children, our finding is insufficient to make such a 
conclusion.  Data from isolated reports are likely to have a 
44smaller study population and accordingly less precise.  
Perhaps it may account for the higher death rate reported 
in single-site studies. Our data suggest higher death 
occurring among those on re-treatment. Patients on re-
treatment for TB are more likely to be non-compliant and 
defaults on treatment due to treatment fatigue, with an 
45 attendant higher risk of dying. Furthermore, TB/HIV co-
46infection is associated with an increased risk of death.  A 
meta-analysis by Jenkins et al. had depicted a higher risk of 
43.death in children with TB/HIV co-infection.  Similarly, an 
earlier meta-analysis had found a higher risk of TB death 
38when associated with HIV in adults.   In contrast, we have 
found a lower rate of death among those with TB/HIV co-
infection. Perhaps the difference may be related to active 
TB case finding among those with HIV and their earlier 
access to care, as well as the time of commencement of TB 
therapy. It is worthy of note that only a few studies 
disaggregated their data by HIV status as such as limiting 
the power of our deduction. However, further studies 
would be needed to fully substantiate the assumption. 
This study has a number of limitations. There are 
unrepresented year bands within the study time frame 
because some studies did not meet the inclusion criteria. It 
was impossible to compute the proportion of TB death in 
studies without clearly defined measures of TB cases or 
with lumped death where we could not delineate death 
due to TB. We also had to exclude studies solely reporting 
high-risk populations such as re-treatment or multidrug-
resistant tuberculosis (MDR-TB). Including such data 
would have created a false high death rate. Many societies 
in Nigeria bury their dead without recourse to 
documentation with relevant authorities. Thus we are 
aware of the inherent likelihood of under-reported death 
in TB occurring outside hospitals. Nevertheless, verbal 
autopsies still represent the next best source of mortality 
data, pending when the country would have a robust, vital 
registration register.
In summation, our meta-analysis has depicted a low 
overall pooled TB death rate in patients on treatment over 
two decades, and a non-significant rise in the rate. These 
findings underpin the need for a concerted effort at 
consolidating earlier gains made in TB control and 
establishing mechanisms to eliminate death from TB, 
culminating in achieving the “End TB Strategy”. Indeed, 
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TB deaths should be preventable with early diagnosis and 
1appropriate treatment.  While we were unable to establish 
HIV treatment status of those with TB/HIV co-infection 
and timing of commencement of HIV treatment, future 
studies should aim to include use of anti-retroviral therapy 
as a potential confounder. This would allow an 
appreciation of the role of HIV treatment in modulating TB 
death.
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